ABSTRACT
There exists an urgent need to develop iterative risk assessment strategies of zoonotic diseases. The aim of this study is to develop a method of prioritizing 98 zoonoses derived from animal pathogens in Japan and to involve four major groups of stakeholders: researchers, physicians, public health officials, and citizens. We used a combination of risk profiling and analytic hierarchy process (AHP). Profiling risk was accomplished with semi-quantitative analysis of existing public health data. AHP data collection was performed by administering questionnaires to the four stakeholder groups. Results showed that researchers and public health officials focused on case fatality as the chief important factor, while physicians and citizens placed more weight on diagnosis and prevention, respectively. Most of the six top-ranked diseases were similar among all stakeholders. Transmissible spongiform encephalopathy, severe acute respiratory syndrome, and Ebola fever were ranked first, second, and third, respectively.
Subject(s)
Data Interpretation, Statistical , Health Priorities , Zoonoses/prevention & control , Animals , Female , Hemorrhagic Fever, Ebola/prevention & control , Humans , Incidence , Japan , Male , Prion Diseases/prevention & control , Public Health , Risk Assessment , Severe Acute Respiratory Syndrome/prevention & control , Surveys and QuestionnairesABSTRACT
Quasiparticle dispersion in Bi2Sr2CaCu2O8 is investigated with improved angular resolution as a function of temperature and doping. Unlike the linear dispersion predicted by the band calculation, the data show a sharp break in dispersion at 50+/-15 meV binding energy where the velocity changes by a factor of 2 or more. This change provides an energy scale in the quasiparticle self-energy. This break in dispersion is evident at and away from the d-wave node line, but the magnitude of the dispersion change decreases with temperature and with increasing doping.
ABSTRACT
We report that the doping and temperature dependence of photoemission spectra near the Brillouin zone boundary of Bi(2)Sr(2)CaCu(2)O(8+delta)exhibit unexpected sensitivity to the superfluid density. In the superconducting state, the photoemission peak intensity as a function of doping scales with the superfluid density and the condensation energy. As a function of temperature, the peak intensity shows an abrupt behavior near the superconducting phase transition temperature where phase coherence sets in, rather than near the temperature where the gap opens. This anomalous manifestation of collective effects in single-particle spectroscopy raises important questions concerning the mechanism of high-temperature superconductivity.
ABSTRACT
Angle-resolved photoemission data from the cuprate superconductor Bi2Sr2CaCu2O8+delta above and below the superconducting transition temperature Tc reveal momentum-dependent changes that extend up to an energy of about 0.3 electron volt, or 40kTc (where k is the Boltzmann constant). The data suggest an anomalous transfer of spectral weight from one momentum to another, involving a sizable momentum transfer Q approximately (0.45pi, 0). The observed Q is intriguingly near the charge-order periodicity required if fluctuating charge stripes are present.
ABSTRACT
Recently, we reported that a ranitidine derivative 2 (fumarate: KW-5092), which had a 2-imidazolidinylidene propanedinitrile moiety (A), showed potent gastrointestinal motility enhancing activity. We have also found that introduction of substituents such as benzyl or 4-fluorobenzyl (i.e., giving 3 or 4) at the N-3 position of the moiety (A) significantly increased this activity. In this study, novel 2-imidazolidinylidene propanedinitrile derivatives possessing a thioether 5-15 were prepared and evaluated for in vitro assays; acetylcholinesterase (AChE) inhibitory activity and potentiating action on electrically induced contractions of guinea pig ileum. Compound 5, in which a nitrogen atom of compound 2 was replaced by a sulfur atom, was more potent than 2 in these tests. Also, in a series of thioether derivatives, introduction of substituents at the N-3 position of the 2-imidazolidinylidene propanedinitrile moiety markedly influenced both activities. In particular, compounds 12 and 13, which showed an excellent potency during in vitro study (AChE IC50 = 3.6 and 2.7 nM; ES. EC30 = 2.1 and 2.5 nM, respectively), were found to be more active in the enhancement of gastrointestinal motility in anesthetized rabbits than their corresponding parent compounds 3 and 4, respectively. In addition, compounds 12 and 13 showed lower affinity for the histamine H2-receptor than ranitidine. Therefore, these compounds may be potent and selective stimulators of gastrointestinal motility.
Subject(s)
Gastrointestinal Motility/drug effects , Imidazoles/chemical synthesis , Nitriles/chemical synthesis , Acetylcholinesterase/metabolism , Animals , Blood Pressure/drug effects , Brain Chemistry/drug effects , Cholinesterase Inhibitors/chemical synthesis , Cholinesterase Inhibitors/chemistry , Cholinesterase Inhibitors/pharmacology , Guinea Pigs , Histamine H2 Antagonists/chemical synthesis , Histamine H2 Antagonists/chemistry , Histamine H2 Antagonists/pharmacology , Ileum/drug effects , Imidazoles/chemistry , Imidazoles/metabolism , Imidazoles/pharmacology , In Vitro Techniques , Male , Molecular Structure , Muscle Contraction/drug effects , Nitriles/chemistry , Nitriles/metabolism , Nitriles/pharmacology , Rabbits , Ranitidine/analogs & derivatives , Rats , Receptors, Histamine H2/metabolism , Sulfides/analysisABSTRACT
In a previous paper, we reported that a novel ranitidine derivative 2 (fumarate: KW-5092), which had a 2-imidazolidinylidene propanedinitrile moiety (A), showed potent gastrointestinal motility enhancing activity. In order to obtain more potent gastrointestinal motility enhancing agents than compound 2 and to examine the effects of various substituents both at a nitrogen atom (B) in the 2-imidazolidinylidene propanedinitrile moiety and a basic nitrogen atom (C), compounds 5-29 were synthesized and evaluated for acetylcholinesterase (AChE) inhibitory activity and potentiating action on electrically stimulated contractions of guinea pig ileum. Introduction of alkyl, benzyl, aryl or acyl groups to the nitrogen (B) or (C), remarkably influenced both activities. Among these, compounds 14 and 15 showed more potent AChE inhibitory activity (IC50 = 6.7, 6.8 nM, respectively) than compound 2 and were active in potentiating action on the ileal contraction (EC30 = 9.5, 11 nM, respectively) together with a negligible histamine H2-receptor blocking property. Furthermore, these compounds were found to be more effective in the enhancement of gastrointestinal motility in anesthetized rabbits than compound 2.
Subject(s)
Gastrointestinal Motility/drug effects , Imidazoles/pharmacology , Nitriles/pharmacology , Animals , Cholinergic Antagonists/pharmacology , Guinea Pigs , Histamine Antagonists , Ileum/drug effects , Imidazoles/chemistry , In Vitro Techniques , Male , Nitriles/chemistry , Rabbits , Ranitidine/chemistryABSTRACT
Ranitidine (1), the histamine H2-receptor antagonist, has been previously reported to increase gastric emptying and gastric motility by inhibition of acetylcholinesterase (AChE) and enhancement of acetylcholine (ACh) release. In order to obtain potent gastroprokinetic agents, a new series of ranitidine derivatives (5-32) possessing a nitrogen atom instead of a sulfur atom (B) was synthesized and their AChE inhibitory activity and potentiating action on electrically evoked contractions of guinea pig ileum were evaluated. Modification of substituents R1 and R2 markedly influenced the activities. In particular, compound 19, (1-[2-[[[5-(piperidinomethyl)-2-furanyl]methyl]amino]-ethyl]-2- imidazolidinylidene)propanedinitrile fumarate, showed 20 and 100 times more potent AChE inhibitory activity and potentiating action on the ileal contraction, respectively, than ranitidine. Furthermore, compound 19 (KW-5092) enhanced gastrointestinal motility in anesthetized rabbits along with a negligible histamine H2-receptor blocking activity.
Subject(s)
Cholinesterase Inhibitors/chemical synthesis , Gastrointestinal Motility/drug effects , Imidazoles/chemical synthesis , Nitriles/chemical synthesis , Ranitidine/analogs & derivatives , Animals , Cholinesterase Inhibitors/pharmacology , Electric Stimulation , Guinea Pigs , Ileum/physiology , Imidazoles/pharmacology , Male , Molecular Structure , Muscle Contraction/drug effects , Neostigmine/pharmacology , Nitriles/pharmacology , Nitrogen , Rabbits , Ranitidine/pharmacology , Structure-Activity RelationshipABSTRACT
We examined the effect of KW-6055 [alpha-(p-butyrylamino-o-nitrobenzyl) pyridine], which has anti-amnesic activity, on the central cholinergic systems of rat frontal cortex using in vivo brain microdialysis. 1) KW-6055 (40, 160 mg/kg, p.o.) increased the extracellular level of ACh in normal rats (257 +/- 23, 202 +/- 24%). The stimulating effect of KW-6055 on ACh release was abolished by tetrodotoxin treatment, supporting that the released ACh was due to neuronal firing. Reserpine pretreatment decreased the effect of KW-6055, indicating that KW-6055 acted on cholinergic neurons through catecholaminergic neurons. 2) In basal forebrain-lesioned rats, KW-6055 (40 mg/kg, p.o.) significantly increased the extracellular level of ACh (251 +/- 22%) for more than 2 hr, which was longer than in normal rats. In conclusion, these results suggest that the stimulating activity on ACh release may be involved in the mechanism of the anti-amnesic effects of KW-6055.
